SCHEMBL5377692

SCHEMBL5377692

CSc1nsc(OCc2ccc(OC(F)(F)F)cc2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
RHEB Q15382 1/20 0.36
PPARA Q07869 2/20 0.36
PPARG P37231 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CYP19A1 P11511 1/20 0.35
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
PTPRZ1 P23471 1/20 0.35
MRGPRX4 Q96LA9 2/20 0.35
MMP1 P03956 1/20 0.35
MMP2 P08253 1/20 0.35
MMP9 P14780 1/20 0.35
MMP14 P50281 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5636919 1.00 MAPK1 (0.39) MAPK1TDP1MEN1KMT2ARHEB
SCHEMBL5373469 0.84 MAOB (0.41) MAPK1TDP1MEN1KMT2ACYP1A2
SCHEMBL5375690 0.84 RAB9A (0.45) MAPK1TDP1MEN1KMT2ACYP1A2
SCHEMBL5378771 0.82 TDP1 (0.56) MAPK1TDP1MEN1KMT2ACYP1A2
SCHEMBL5417437 0.81 MEN1 (0.41) MAPK1TDP1MEN1KMT2ACYP1A2
SCHEMBL5387366 0.80 APP (0.42) MAPK1TDP1MEN1KMT2ACYP1A2
SCHEMBL5383575 0.80 APP (0.42) MAPK1TDP1MEN1KMT2ACYP1A2
SCHEMBL5377736 0.79 LMNA (0.47) MAPK1TDP1MEN1KMT2APPARG
SCHEMBL5378135 0.75 MAOB (0.46) L3MBTL1ALDH1A1
SCHEMBL5389191 0.74 LMNA (0.46) MEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070293510-A1 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED ( A JAPANESE CORPORATION) (JP) 2007-12-20 US disclosed
US-20070293510-A1 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED ( A JAPANESE CORPORATION) (JP) 2007-12-20 US disclosed
US-7273879-B2 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-25 US disclosed
US-7273879-B2 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-25 US disclosed
US-7273879-B2 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-25 US disclosed
US-20050215578-A1 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-09-29 US disclosed
EP-1475374-A1 THIADIAZOLE COMPOUNDS AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2004-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215578-A1 Thiadiazole compounds and use thereof C5, C3AR1, TH MAPK1 509/4885TDP1 1173/4885MEN1 2386/4885
US-20070293510-A1 Thiadiazole compounds and use thereof C5, C3AR1, TH MAPK1 488/4885TDP1 1150/4885MEN1 2301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.